Global /United States /Healthcare /Biotechnology /CBIO

Crescent Biopharma, Inc.

CBIO

• NASDAQ: CBIO • Delayed

20.97USD -13%

As of 14 June 2026, Crescent Biopharma, Inc. has a market cap of $693.16M USD, ranking #13003 globally and #2426 in the United States. It ranks #1180 in the Healthcare sector, and #219 in the Biotechnology industry.

Global Rank

13003

Country Rank

2426

Sector Rank

1180

Industry Rank

219

Key Stats

Market Cap

$693.16MUSD

Enterprise Value

$481.61MUSD

Revenue (TTM)

$10.84MUSD

EBITDA (TTM)

-$152.55MUSD

Net Income (TTM)

-$153.94MUSD

PS Ratio

63.9

PB Ratio

3.5

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Biotechnology

CEO

Joshua Brumm open_in_new

Employees

Founded

2003

Website

crescentbiopharma.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-13%	-22%	38%	95%	68%	77%	11%	-90%	-94%

News

CBIO Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	CBIO Crescent Biopharma Inc ISIN: KYG2545C1042 Shares Out.: Shares Outstanding: 27.572M¹ Shares Float: 21.662M² TV: TradingView: NASDAQ: CBIO SA: Stock Analysis: NASDAQ: CBIO YF: Yahoo Finance: CBIO GF: Google Finance: NASDAQ: CBIO NQ: NASDAQ: CBIO BA: Barron's: CBIO MS: Morningstar: XNAS: CBIO	20.97 USD	TV: TradingView: NASDAQ: CBIO SA: Stock Analysis: NASDAQ: CBIO YF: Yahoo Finance: CBIO GF: Google Finance: NASDAQ: CBIO NQ: NASDAQ: CBIO BA: Barron's: CBIO MS: Morningstar: XNAS: CBIO

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Crescent Biopharma, Inc.

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.

Similar Companies

Industry: Biotechnology (United States)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 26K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 23K%	19.0	United States
Natera, Inc. NASDAQ: NTRA	$27.6B 4K%	-	United States
IQVIA Holdings Inc. NYSE: IQV	$26.3B 4K%	20.0	United States
United Therapeutics Corp. NASDAQ: UTHR	$25.03B 4K%	20.4	United States
Moderna, Inc. NASDAQ: MRNA	$18.13B 3K%	-	United States

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
argenx SE EBR: ARGX	$47.84B 41.39B EUR 7K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 6K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 6K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 6K%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$28.11B 42.76T KRW 4K%	43.8	South Korea
BioNTech SE NASDAQ: BNTX	$25.69B 4K%	-	Germany

chevron_leftBack